We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

InPractice Survey on the Treatment of Hypercholesterolemia

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00523796
First Posted: September 3, 2007
Last Update Posted: February 16, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
AstraZeneca
  Purpose
This is a multi-centre survey of patients who are currently on lipid-lowering pharmacological treatment. Data collection for each patient will take place at one visit.

Condition
Hypercholesterolemia

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: InPractice Survey on the Treatment of Hypercholesterolemia

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Estimated Enrollment: 2500
Study Start Date: February 2007
Study Completion Date: November 2007
Primary Completion Date: November 2007 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
primary care
Criteria

Inclusion Criteria:

  • Subject must be 18 years of age or older of either sex.
  • Subject is on lipid-lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks.

Exclusion Criteria:

  • Subjects who are unwilling or unable to provide informed consent.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00523796


Locations
Vietnam
Research Site
Hanoi, Vietnam
Sponsors and Collaborators
AstraZeneca
Investigators
Study Chair: Pham Gia Khai, Prof Vietnamese Cardiovascular Association
Study Chair: Nguyen Manh Phan, Prof Vietnamese Cardiovascular Association
Study Director: Than Trong Son, MD AstraZeneca
  More Information

Additional Information:
ClinicalTrials.gov Identifier: NCT00523796     History of Changes
Other Study ID Numbers: NIS-CVN-CRE-2007/1
VN-NIS-0001 ( Other Identifier: NIS Registry )
First Submitted: August 30, 2007
First Posted: September 3, 2007
Last Update Posted: February 16, 2011
Last Verified: February 2011

Keywords provided by AstraZeneca:
dyslipidemia
in practice survey
Vietnam

Additional relevant MeSH terms:
Hypercholesterolemia
Hyperlipidemias
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases